Bimekizumab has demonstrated robust efficacy in both psoriatic arthritis and axial spondyloarthritis, encompassing both radiographic and non-radiographic forms, including patients who have previously failed anti-TNF therapy. This evidence concerns the gene TNF and psoriatic arthritis.